Slingluff C L, Seigler H F
Department of Surgery, Duke University Medical Center, Durham, NC.
Ann Plast Surg. 1992 Jan;28(1):110-3. doi: 10.1097/00000637-199201000-00028.
Systemic therapy for metastatic malignant melanoma has been disappointing. The search for alternate therapeutic methods includes investigation of the interaction between melanoma and the human immune system. A cellular immune response to melanoma has been documented in vitro and in vivo. In most patients with disseminated disease, however, immune T cells fail to eradicate the tumor. While this phenomenon is poorly understood, the occasional occurrence of spontaneous regression provides some indication that the immune response may, in fact, be capable of eradicating established tumor in vivo. Current efforts to augment and to direct the immune response to melanoma include investigation of specific and nonspecific adoptive immunotherapy. Specific therapy includes the generation of tumor-activated specific killer cells from peripheral blood, draining nodes, or metastatic tumor deposits. An increasing understanding of antigen recognition and improved methodology for T-cell culture are contributing toward the application of cellular immunotherapy to patients with melanoma.
转移性恶性黑色素瘤的全身治疗一直令人失望。寻找替代治疗方法包括研究黑色素瘤与人体免疫系统之间的相互作用。体外和体内均已证明对黑色素瘤存在细胞免疫反应。然而，在大多数播散性疾病患者中，免疫T细胞无法根除肿瘤。虽然这种现象尚不清楚，但偶尔出现的自发消退提供了一些迹象，表明免疫反应实际上可能能够在体内根除已形成的肿瘤。目前增强和引导对黑色素瘤免疫反应的努力包括研究特异性和非特异性过继免疫疗法。特异性疗法包括从外周血、引流淋巴结或转移性肿瘤沉积物中产生肿瘤激活的特异性杀伤细胞。对抗原识别的深入了解和T细胞培养方法的改进，有助于将细胞免疫疗法应用于黑色素瘤患者。
